Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply.
Departments of Medicine, Epidemiology and Biostatistics, Western University, London, Ontario, Canada.|Robarts Clinical Trials Inc., London, Ontario, Canada.
V
0000-0002-1092-0033
V
Jairath
Robarts Clinical Trials Inc., London, Ontario, Canada.|Department of Medicine, University of California San Diego, La Jolla, CA, USA.
N
N
Vande Casteele
Robarts Clinical Trials Inc., London, Ontario, Canada.|Department of Gastroenterology, University hospital of Ghent, Ghent, Belgium.
P
P
Hindryckx
D000911:Antibodies, Monoclonal; D003093:Colitis, Ulcerative; D006801:Humans; D007166:Immunosuppressive Agents; D000069285:Infliximab
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab